Medicus Pharma (NASDAQ:MDCX) Rating Increased to Strong-Buy at D Boral Capital

Medicus Pharma (NASDAQ:MDCX) was upgraded by stock analysts at D Boral Capital to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

MDCX has been the subject of several other research reports. D. Boral Capital assumed coverage on shares of Medicus Pharma in a research note on Monday. They set a “buy” rating and a $14.00 target price for the company. Maxim Group initiated coverage on Medicus Pharma in a research note on Tuesday, December 17th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Brookline Capital Management upgraded Medicus Pharma to a “strong-buy” rating in a research note on Monday, December 23rd.

Medicus Pharma Trading Up 0.8 %

MDCX opened at $3.61 on Monday. The firm has a 50-day simple moving average of $3.46. Medicus Pharma has a one year low of $1.80 and a one year high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.14. On average, research analysts expect that Medicus Pharma will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma comprises about 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th biggest position. Interchange Capital Partners LLC owned 13.43% of Medicus Pharma as of its most recent filing with the Securities & Exchange Commission.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.